Kylo-0603
Asset
Selectively activates hepatic thyroid hormone receptor beta to regulate lipid metabolism and reduce liver fat, inflammation, and fibrosis.
- Stage
- Phase 2
- Modality
- Small molecule
- Target
- Not known
- 1
- Indication
- 1
- Trial
- 1
- Developer
Indications
1Metabolic dysfunction-associated steatoic liver disease
Phase 2, Not yet recruiting, NCT07878091, clinicaltrials.gov, Oct 17, 2026
In the full profile
- Owner and partners1
- Trials1
- Signals1
Every asset’s record: target, stage, trials and the evidence behind it.